Utilization of polymerase chain reaction technology in the detection of solid tumors

Cancer

Volumn 82, Issue 8, 1998, Pages 1419-1442

  Raj, Ganesh V ^a   Moreno, Jose G ^b   Gomella, Leonard G ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cancer; Detection; Metastasis; Polymerase chain reaction; Reverse transcriptase polymerase chain reaction; Solid tumors

Indexed keywords

TUMOR MARKER;

ABDOMINAL CANCER; BREAST CARCINOMA; CANCER DIAGNOSIS; COLORECTAL CANCER; EWING SARCOMA; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; LUNG CARCINOMA; MELANOMA; METASTASIS; NEUROECTODERM TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SOLID TUMOR; THYROID CARCINOMA; URINARY TRACT CANCER;

DNA, NEOPLASM; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; POLYMERASE CHAIN REACTION; RNA-DIRECTED DNA POLYMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 0032522958     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980415)82:8<1419::AID-CNCR1>3.0.CO;2-4     Document Type: Review

References (257)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-28.
2. Fidler JF. Critical factors in the biology of human cancer metastasis: twenty-eighth G. H. A. Clowes memorial award lecture. Cancer Res 1990;50:6130-8.
3. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels and pulmonary metastases following tumor implantation. Cancer Res 1974;34:997.
4. Eisenstein BI. The polymerase chain reaction: a new method of using molecular genetics for medical diagnosis. N Engl J Med 1990;322(3):178-82.
5. Saiki RK, Bugawan T, Horn G, Mullis K, Erlich H. Analysis of enzymatically amplified beta-globin and HLA-DQ DNA with allele-specific oligonucleotide probes. Nature 1986;324:163.
6. Saiki RK, Gelfand DH, Stoffel S. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988;239:487.
7. Saiki RK, Scharf S, Faloona F. Enzymatic amplification of B-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985;230:1350.
8. Mullis KB, Faloona FAS. Specific synthesis of DNA in vitro via a polymerase catalyzed chain reaction. Methods Enzymol 1987;155:335.
9. Sievers EL, Loken MR. Detection of minimal residual disease in acute myelogenous leukemia. J Pediatr Hematol Oncol 1995;17:123-33.
10. Arnheim N, Erlich HA. Polymerase chain reaction strategy. Annu Rev Biochem 1992;61:131-56.
11. Popescu NC, Zimonjic DB. Molecular cytogenetic characterization of cancer cell alterations. Cancer Genet Cytogenet 1997;93:10-21.
12. Hooberman AL. The use of the polymerase chain reaction in clinical oncology. Oncology (Huntingt) 1934;6:25-34.
13. Bell DA. Detection of DNA sequence polymorphisms in carcinogen metabolism genes by polymerase chain reaction. Environ Mol Mutagen 1991;18:245-8.
14. Lyons J. The polymerase chain reaction and cancer diagnostics [review, 32 references]. Cancer 1992;69:1527-31.
15. Pelkey TJ, Frierson HF Jr., Bruns DE. Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors. Clin Chem 1996;42:1369-81.
16. Katz AE, Devries GM, Begg MD. Enhanced reverse transcriptase polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer 1994;75:1642-8.
17. Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, et al. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 1995;13:1195-200.
18. Wood DP, Banks ER, Humphreys S, Rangnekar VM. Sensitivity of immunohistochemistry and polymerase chain reaction in detecting prostate cancer cells in bone marrow. J Histochem Cytochem 1994;42:505-11.
19. Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Wittle ON, et al. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci U S A 1988;85:5698-702.
20. Roth MS, Terry VH. Application of the polymerase chain reaction for detection of minimal residual disease of hematologic malignancies. Henry Ford Hosp Med J 1991;39:112-6.
21. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991;338:1227-9.
22. Offit K, Gilewski T, McGuire P, Schluger A, Hampel H, Brown K, et al. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet 1996;347:1643-5.
23. Lee MS, Chang KS, Cabanillas F, Freirreich EJ, Trujillo JM, Stass SA. Detection of minimal residual cell carrying the t(14;18) by DNA sequence amplification. Science 1987; 237:175.
24. Crescenzi M, Seto M, Herzig GP, Weiss PD, Griffith RC, Korsmeyer SJ. Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease. Proc Natl Acad Sci U S A 1988;85:4869-73.
25. Ngan BY, Nourse J, Cleary ML. Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas. Blood 1989;73:1759-62.
26. Gribben J, Nadler L. Detection of minimal residual disease [review, 94 references]. Cancer Treat Res 1995;76:249-70.
27. Miyamura K, Tanimoto M, Morishima Y, Horibe K, Yamamoto K, Akatsuka M, et al. Detection of Philadelphia chromosome positive acute lymphostatic leukemias by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation. Blood 1992;79:1366-70.
28. DeVita VT, Hellman S, Rosenberg SA. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven, 1997.
29. Blennerhassett GT, Furth ME, Anderson A, Burns JP, Changanti RS, Blick M, et al. Clinical evaluation of a DNA probe assay for the Philadelphia (Ph1) translocation in chronic myelogenous leukemia. Leukemia 1988;2:648-57.
30. Westbrook CA. The role of molecular techniques in the clinical management of leukemia: lessons from the Philadelphia chromosome [review, 40 references]. Cancer 1992;70:1695-700.
31. Gabert J, Thuret I, Lafage M, Carcassonne Y, Maraninchi D, Mannoni P. Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myeloid leukaemia patients after bone-marrow transplantation. Lancet 1989; 2:1125-8.
32. Tkachuk DC, Westbrook CA, Andreeff M, Donlon TA, Cleary ML, Suryanarayan K, et al. Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization. Science 1990;250:559-62.
33. Moos M, Schulz R, Cremer F, Sucker C, Schmohl D, Dohner H, et al. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies. Stem Cells 1995;13(Suppl 3):42-51.
34. Adams V, Hany MA, Schmid M, Hassam S, Briner J, Niggli FK. Detection of t(11;22)(q24;q12) translocation breakpoint in paraffin-embedded tissue of the Ewing's sarcoma family bv nested reverse transcription-polymerase chain reaction. Diagn Mol Pathol 1996;5:107-13.
35. Downing JR, Khandekar A, Shurtleff SA, Head DR, Parham DM, Webber BL, et al. Multiplex RT-PCR assay for the differential diagnosis of alveolar rhabdomyosarcoma and Ewing's sarcoma. Am J Pathol 1995;146:626-34.
36. Sorensen PH, Shimada H, Liu XF, Lim JF, Thomas G, Triche TJ. Biphenotypic sarcomas with myogenic and neural differentiation express the Ewing's sarcoma EWS/FLI1 fusion gene. Cancer Res 1995;55:1385-92.
37. Sorensen PH, Liu XF, Delattre O, Rowland JM, Biggs CA, Thomas G, et al. Reverse transcriptase PCR amplification of EWS/FLI-1 fusion transcripts as a diagnostic test for peripheral primitive neuroectodermal tumors of childhood. Diagn Mol Pathol 1993;2:147-57.
38. Downing JR, Head DR, Parham DM, Douglas EC, Hulshof MG, Link MP, et al. Detection of the (11;22)(q24;q12) translocation of Ewing's sarcoma and peripheral neuroectodermal tumor by reverse transcription polymerase chain reaction. Am J Pathol 1993;143:1294-300.
39. Ida K, Kobayashi S, Taki T, Hanada R, Bessho F, Yamamori S, et al. EWS-FLI-1 and EWS-ERG chimeric mRNAs in Ewing's sarcoma and primitive neuroectodermal tumor. Int J Cancer 1995;63:500-4.
40. Argatoff LH, O'Connell JX, Mathers JA, Gilks CB, Sorensen PH. Detection of the EWS/WT1 gene fusion by reverse transcriptase-polymerase chain reaction in the diagnosis of intra-abdominal desmoplastic small round cell tumor. Am J Surg Pathol 1996;20:406-12.
41. Croce CM, Nowell PC. Molecular basis of human B cell neoplasia. [review, 37 references]. Blood 1985;65:1-7.
42. Showe LC, Croce CM. The role of chromosomal translocations in B- and T-cell neoplasia. [review, 82 references]. Annu Rev Immunol 1987;5:253-77.
43. Lonn U, Lonn S, Nilsson B, Stenkvist B. Prognostic value of erb-B2 and myc amplification in breast cancer imprints. Cancer 1995;75:2681-7.
44. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith LE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
45. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
46. Neumaier M, Gerhard M, Wagener C. Diagnosis of micrometastases by the amplification of tissue-specific genes. Gene 1995;159:43-7.
47. Waha A, Rollbrocker B, Wiestler OD, von Deimling A. A polymerase chain reaction-based assay for the rapid detection of gene amplification in human tumors. Diagn Mol Pathol 1996;5:147-50.
48. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc sequences in primary human neuroblastomas: correlation with advanced disease stage. Prog Clin Biol Res 1985;175:105-13.
49. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
50. Seeger RC, Wada R, Brodeur GM, Moss TJ, Bjork RL, Sousa L, et al. Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Prog Clin Biol Res 1988;271:41-9.
51. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
52. Lonn U, Lonn S, Nylen U, Stenkvist B. Appearance and detection of multiple copies of the mdr-1 gene in clinical samples of mammary carcinoma. Int J Cancer 1992;51:682-6.
53. Brisco MJ, Condon J, Hughes E, Neon SH, Sykes PJ, Seshadri R, et al. Prognostic significance of detection of monoclonality in remission marrow in acute lymphoblastic leukemia in childhood. Australian and New Zealand Children's Cancer Study Group. Leukemia 1993;7:1514-20.
54. Speicher MR. Microsatellite instability in human cancer. [review, 87 references]. Oncol Res 1995;7:267-75.
55. Mao L, Schoenberg MP, Scicchitano M, Erozan YS, Merio A, Schwab D, et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996;271:659-62.
56. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 1996;2:1035-7.
57. Loda M. Polymerase chain reaction-based methods for the detection of mutations in oncogenes and tumor suppressor genes. [review, 86 references]. Hum Pathol 1994;25:564-71.
58. Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992;256:102-5.
59. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988;16:7773-82.
60. Bos JL, Fearon ER, Hamilton SR, Verlaan de Vries M, van Boom JH, van der Eb AJ, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987;327:293-7.
61. Nollau P, Moser C, Weinland G, Wagener C. Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR. Int J Cancer 1996;66:332-6.
62. Hardingham JE, Kotasek D, Sage RE, Eaton MC, Pascoe VH, Dobrovic A. Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease. Mol Meet 1995;1:789-94.
63. Jiang W, Kahn SM, Guillem JG, Lu SH, Weinstein IB. Rapid detection of ras oncogenes in human tumors: applications to colon, esophageal, and gastric cancer. Oncogene 1989;4:923-8.
64. Inoue S, Nakao A, Kasai Y, Harada A, Nonami T, Takagi H. Detection of hepatic micrometastasis in pancreatic adenocarcinoma patients by two-stage polymerase chain reaction/ restriction fragment length polymorphism analysis. Jpn J Cancer Res 1995;86:626-30.
65. Uehara H, Nakaizumi A, Baba M, Iishi H, Tatsuta M, Kitamura T, et al. Diagnosis of pancreatic cancer by K-ras point mutation and cytology of pancreatic juice. Am J Gastroenterol 1996;91:1616-21.
66. Nomoto S, Nakao A, Kasai Y, Harada A, Nonami T, Takagi H. Detection of ras gene mutations in perioperative peripheral blood with pancreatic adenocarcinoma. Jpn J Cancer Res 1996;87:793-7.
67. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990;5:1037-43.
68. Saito S. Detection of H-ras gene point mutations in transitional cell carcinoma of human urinary bladder using polymerase chain reaction. Keio J Med 1992;41:80-6.
69. Shibata D, Capella G, Perucho M. Mutational activation of the c-K-ras gene in human pancreatic carcinoma [review, 96 references]. Baillieres Clin Gastroenterol 1990;4:151-69.
70. Tada M, Omata M, Kawai S, Saisho H, Ohio M, Saiki RK, et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993;53:2472-4.
71. van Mansfeld AD, Bos JL. PCR-based approaches for detection of mutated ras genes [review, 43 references]. PCR Methods Appl 1992;1:211-6.
72. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991;252:706-9.
73. Yoshimura I, Kudoh J, Saito S, Tazaki H, Shimizu N. p53 gene mutation in recurrent superficial bladder cancer. J Urol 1995;153:1711-5.
74. Suzuki H, Komiya A, Aida S, Ito H, Yatani R, Shimazaki J. Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer. Prostate 1996;28:318-24.
75. Osbourne RJ, Merlo GR, Mitsudomi T, Venesio T, Liscia DS, Cappa AP. Mutations in the p53 gene in primary human breast cancers. Cancer Res 1991;51:6194-8.
76. Ngan HY, Stanley M, Liu SS, Ma HK. HPV and p53 in cervical cancer. Genitourin Med 1994;70:167-70.
77. Mashiyama S, Murakami Y, Yoshimoto T, Sekiya T, Hayashi K. Detection of p53 gene mutations in human brain tumors by single strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1991;6:1313-8.
78. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
79. Onisto M, Riccio MP, Scannapieco P, Caenazzo C, Griggio L, Spina M, et al. Gelatinase A/TIMP-2 imbalance in lymphnode-positive breast carcinomas, as measured by RT-PCR. Int J Cancer 1995;63:621-6.
80. Rodriguez C, Monges G, Rouanet P, Dutrillaux B, Lefrancois D, Theillet C. CD44 expression patterns in breast and colon tumors: a PCR-based study of splice variants. Int J Cancer 1995;64:347-54.
81. Tarin D, Bolodeoku J, Hatfill SJ, Sugino T, Woodman AC, Yoshida K. The clinical significance of malfunction of the CD44 locus in malignancy. [review, 59 references]. J Neurooncol 1995;26:209-19.
82. Tarin D, Matsumura Y. Deranged activity of the CD44 gene and other loci as biomarkers for progression to metastatic malignancy. [review, 39 references]. J Cell Biochem Suppl 1993;17G:173-85.
83. Terpe HJ, Storkel S, Zimmer U, Anquez V, Fischer C, Pantel K, et al. Expression of CD44 isoforms in renal cell tumors: positive correlation to tumor differentiation. Am J Pathol 1996;148:453-63.
84. zur Hausen H. Viruses in human cancers. Science 1991;254: 1167-73.
85. Rose BR, Jiang XM, Thompson CH, Tattersall MH, Cossart YE. Detection of human papillomavirus type 16 E6/E7 transcripts in fixed paraffin-embedded cervical cancers by the polymerase chain reaction. J Virol Methods 1991;35:305-13.
86. Rose BR, Thompson CH, Jiang XM, Tattersall MH, Elliot PM, Cossart YE, et al. Detection of human papillomavirus type 16 E6/E7 transcripts in histologically cancer-free pelvic lymph nodes of patients with cervical carcinoma. Gynecol Oncol 1994;52:212-7.
87. Park JS, Chee YH, Namkoong SE, Han SK, Kim TE, Lee HY, et al. Human papillomavirus detection in cervical carcinoma tissues and paraaortic lymph nodes by the polymerase chain reaction. Gynecol Oncol 1994;53:344-51.
88. Czegledy J, Iosif C, Hansson BG, Evander M, Gergely L, Wadell G. Can a test for E6/E7 transcripts of human papillomavirus type 16 serve as a diagnostic tool for the detection of micrometastasis in cervical cancer? Int J Cancer 1995;64:211-5.
89. Mvula M, Iwasaka T, Matsuo N, Nakao Y, Kaku T, Hachisuga T, et al. Detection of human papillomavirus types 16 and 18 in primary and in metastatic lesions of cervical carcinomas. Gynecol Oncol 1994;53:156-60.
90. Shibata D, Cosgrove M, Arnheim N, Martin J, Martin SE. Detection of human papillomavirus DNA in fine needle aspirations of metastatic sqamous cell carcinoma of the uterine cervix using the polymerase chain reaction. Diagn Cytopathol 1989;4:40-3.
91. Syrjanen KJ. Human papillomavirus in genital carcinogenesis [review, 19 references]. Sex Transm Dis 1994;21:S86-9.
92. Pao CC, Hor JJ, Yang FP, Lin CY, Tseng CJ. Detection of human papillomavirus mRNA and cervical cancer cells in peripheral blood of cervical cancer patients with metastasis. J Clin Oncol 1997;15:1008-12.
93. Romano N, Romano FM, Viviano E, Vitale F, Villafrate MR, Perna AM, et al. Rare association of human herpesvirus 6 DNA with human papillomavirus DNA in cervical smears of women with normal and abnormal cytologies. J Clin Microbiol 1996;34:1589-91.
94. Otsuki T, Kumar S, Ensoli B, Kingma DW, Dano T, Stetler-Stevenson M, et al. Detection of HHV-8/KSHV DNA sequences in AIDS-associated extranodal lymphoid malignancies. Leukemia 1996;10:1358-62.
95. Wang H, Chen M, Berneman ZN, Delgado G, DiPaolo JA. Detection of human herpesvirus-6 in paraffin-embedded tissue of cervical cancer by polymerase chain reaction. J Virol Methods 1994;47:297-305.
96. Wang Y, Holland JF, Bleiweiss IJ, Melena S, Lin X, Pelisson I, et al. Detection of mammary tumor virus env gene-like sequences in human breast cancer. Cancer Res 1995; 55:5173-9.
97. Takeda S, Shibata M, Morishima T, Harada A, Nakao A, Takagi H, et al. Hepatitis C virus infection in hepatocellular carcinoma: detection of plus-strand and minus-strand viral RNA. Cancer 1992;70:2255-9.
98. Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Mullholland SG, et al. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 1992; 2:6110-2.
99. Moreno JG, O'Hara M, Long JP, Veltri RW, Ning X, Alexander AA, et al. Transrectal ultrasound guided biopsy causes hematogenous dissemination of prostate cells into the circulation as determined by RT-PCR of PSA. Urology 1997;49:515-20.
100. Moreno JG, Shenot P, Byrne DS, Gomella LG. Analysis of tumor spillage during radical prostatectomy using RT-PCR of prostate specific antigen. Techniques Urol 1996;2:54-7.
101. Olsson CA, Devries GM, Raffo AJ, Benson MC, O'Toole K, Cao Y, et al. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J Urol 1996;155:1557-62.
102. Oelfelein MG, Herz B, Ignatoff JM, Kaul KL. Longitudinal assessment by prostate specific antigen (PSA) reverse transcriptase polymerase chain reaction (RT-PCR) of circulating prostate epithelial cells following a retropubic radical prostatectomy. J Urol 1996;155:552a.
103. Oelfelein MG, Kaul KL, Herz B, Blum MD, Holland JM, Keeler TC, et al. Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy. J Urol 1997;155:238-42.
104. Cama C, Olsson CA, Raffo AJ, Perlman H, Buttyan R, O'Toole K, et al. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J Urol 1995;153:1373-8.
105. Cama CL, Olsson CA, Buttyan RE, Wise GJ, Devries GM, Katz AE. Molecular staging of prostate cancer. III. Effects of digital rectal examination, cystoscopy and needle biopsy on the enhanced reverse transcriptase polymerase chain reaction. J Urol 1996;155:553A.
106. Israeli RS, Miller WH, Su SL, Samadi DS, Powell CT, Heston WD, et al. Sensitive detection of prostate hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane derived primers in the polymerase chain reaction. J Urol 1995;153:573-7.
107. Israeli RS, Miller WH Jr., Su SL, Powell CT, Fair WR, Samadi DS, et al. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 1994; 54:6306-10.
108. Jaakkola S, Vornanen T, Leioninen J, Rannikko S, Stenman U. Detection of prostatic cells in peripheral blood: correlation with serum concentrations of prostatic specific antigen. Clin Chem 1995;41:182-6.
109. Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Halton E, et al. Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 1994;12:2634-9.
110. Loric S, Dumas F, Eschwege P, Balnchet P, Benoit G, Jardin A, et al. Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. Clin Chem 1995;41:1698-704.
111. Miyajima Y, Horibe K, Fukuda M, Matsumoto K, Numata S, Mori H, et al. Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer 1997;77:1214-9.
112. Naito H, Kuzumaki N, Uchino J, Kobayashi R, Shikano T, Ishikawa Y, et al. Detection of tyrosine hydroxylase mRNA and minimal neuroblastoma cells by the reverse transcriptase polymerase chain reaction. Eur J Cancer 1991;27:762-5.
113. Yakubovskaya MS, Spiegelman V, Luo FC, Malaev S, Slanev A, Zobrovskaya I, et al. High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer. Int J Cancer 1995; 63:810-4.
114. Brossart P, Keilholz U, Scheibenbogen C, Mohler T, Willhauck M, Hunstein W. Detection of residual tumor cells in patients with malignant melanoma responding to immunotherapy. J Immunother 1994;15:38-41.
115. Brossart P, Schmier JW, Kruger S, Willhauck U, Scheibenbogen C, Mohler T, et al. A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res 1995;55:4065-8.
116. Van der Velde-Zimmermann D, Roijers JF, Bouwens-Rombouts A, De Weger RA, De Graaf PW, Tolanus MG, et al. Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. Am J Pathol 1996;149:759-64.
117. Kunter U, Buer J, Probst M, Duensing S, Dullman I, Grosse J, et al. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst 1996;88:590-4.
118. Stevens GL, Scheer WD, Levine EA. Detection of tyrosinase mRNA from the blood of melanoma patients. Cancer Epidemiol Biomarkers Prev 1996;5:293-6.
119. Foss AJ, Guille MJ, Occleston NL, Hykin PG, Hungerford JL, Lightman S, et al. The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 1995;72:155-9.
120. Wang X, Heller R, VanVoorhis N, Cruse CW, Glass F, Fenske N, et al. Detection of sub-microscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994;220:768-74.
121. Battayani Z, Grob JJ, Xerri L, Noe C, Zarour H, Houvaeneghel G, et al. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 1995;131:443-7.
122. Hoon DS, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995;13:2109-16.
123. Jonas S, Windeatt S, O-Boateng A, Fordy C, Allen-Mersh TG. Identification of carcinoembryonic antigen-producing cells circulating in the blood of patients with colorectal carcinoma by reverse transcriptase polymerase chain reaction. Gut 1996;39:717-21.
124. Mori M, Mimori K, Inoue H, Barnard G, Tsuji K, Nanbara S, et al. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1995;55:3417-20.
125. Mori M, Mimori K, Ueo H, Karimine N, Barnard GF, Sugimachi K, et al. Molecular detection of circulating solid carcinoma cells in the peripheral blood: the concept of early systemic disease. Int J Cancer 1996;68:739-43.
126. Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Wagener C, Neumaier M. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 1994;12:725-9.
127. Doi F, Chi DD, Charuworn BB, Conrad AJ, Russel J, Morton DL, et al. Detection of beta-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma. Int J Cancer 1996;65:454-9.
128. Hoon DS, Sarantou T, Doi F, Chi DD, Charuworn BB, Conrad AJ, et al. Detection of metastatic breast cancer by beta-hCG polymerase chain reaction. Int J Cancer 1996;69:369-74.
129. Lehrer S, Terk M, Piccoli SP, Song HK, Lavagnini P, Luderer AA. Reverse transcriptase-polymerase chain reaction for prostate-specific antigen may be a prognostic indicator in breast cancer. Br J Cancer 1996;74:871-3.
130. Schlegel J, Bocker T, Zirngibl H, Hofstadter F, Ruschoff J. Detection of microsatellite instability in human colorectal carcinomas using a non-radioactive PCR-based screening technique. Virchows Arch 1995;426:223-7.
131. Sugino T, Yoshida K, Bolodeoku J, Tahara H, Buley I, Manek S, et al. Telomerase activity in human breast cancer and benign breast lesions: diagnostic applications in clinical specimens, including fine needle aspirates. Int J Cancer 1996;69:301-6.
132. Rinker-Schaeffer CW, Chekmareva MA, Mohler JL. The role of motility proteins and metastasis-suppressor genes in prostate cancer progression. [review, 50 references]. Stem Cells 1996;14:508-16.
133. De Wit PE, Van Muijen GN, De Waal RM, Ruiter DJ. Pathology of malignant melanoma, including new markers and techniques in diagnosis and prognosis [review, 69 references]. Curr Opin Oncol 1996;8:143-51.
134. Bicknell R, Harris AL. Mechanisms and therapeutic implications of angiogenesis. Curr Opin Oncol 1996;8:60-5.
135. Jacobs SS. Spread of prostate cancer to bone. Urology 1983;21:337-44.
136. Warren S, Harris PN, Graves RC. Osseous metastasis of carcinoma of the prostate. Arch Pathol 1936;22:139.
137. Whitmore WF. The natural history of prostate cancer. Arch Pathol 1936;22:139.
138. Edamato Y, Tani M, Kurata T, Abe K. Hepatitis C and B virus infections in hepatocellular carcinoma: analysis of direct detection of viral genome in paraffin embedded tissues. Cancer 1996;77:1787-91.
139. Edelstein RA, Zietman A, De Las Morenas A, Krane RJ, Babayab RK, Dallow KC, et al. Implications of prostatic micrometastases to the pelvic lymph nodes: first report of an archival tissue gene expression study. J Urol 1996;155:550A.
140. Edelstein RA, Krane RJ, Babayan RK, de las Morenas A, Moreland RB. A rapid and simple method for the detection of prostate-specific antigen mRNA in archival tissue specimens using a reverse transcription-polymerase chain reaction assay. Urology 1995;45:597-603.
141. Wood DP. The molecular staging of prostate cancer. Semin Urol 1995;13:96-102.
142. Deguchi T, Doi T, Ehara H, Ho S, Takahashi Y, Nishino Y, et al. Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1993;53:5350-4.
143. Fields KK, Elfenbein GJ, Trudeau WL, Perkins JB, Janssen WE, Moscinski LC. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996;14:1868-76.
144. Kvalheim G. Detection of occult tumour cells in bone marrow and blood in breast cancer patients: methods and clinical significance. Acta Oncol 1996;35(Suppl 8):13-8.
145. Wood DP, Weinstein M, Humphreys S, Rangnekar VM. Identification of bone marrow micrometastases in patients with prostate cancer. Cancer 1994;74:2533-40.
146. Bretten PR, Melamed MR, Fair WR, Cote RJ. Detection of occult micrometasteses in the bone marrow of patients with prostate cancer. Cancer 1991;68:1895-8.
147. Deguchi T, Yang M, Ehara H, Ito S, Nishino Y, Takahashi Y, et al. Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer. Br J Cancer 1997;75:634-8.
148. Davidson LA, Jiang YH, Lupton JR, Chapkin RS. Noninvasive detection of putative biomarkers for colon cancer using fecal messenger RNA. Cancer Epidemiol Biomarkers Prev 1995;4:643-7.
149. Itoh F, Suzuki A, Hinoda Y, Imai K. Double determinant immuno-polymerase chain reaction for detecting soluble intercellular adhesion molecule-1. Artif Organs 1996;20:898-901.
150. Yoshida K, Sugino T, Goodison S, Warren BF, Nolan D, Wadsworth S, et al. Detection of telomerase activity in exfoliated cancer cells in colonic luminal washings and its related clinical implications. Br J Cancer 1997;75:548-53.
151. Gotley DC, Reeder JA, Fawcett J, Walsh MD, Bates P, Simmons DL, et al. The deleted in colon cancer (DCC) gene is consistently expressed in colorectal cancers and metastases. Oncogene 1996;13:787-95.
152. Johnson LD, Hunt DM, Kim K, Nachtigal M. Amplification of stromelysin-3 transcripts from carcinomas of the colon. Hum Pathol 1996;27:964-8.
153. Cawkwell L, Bell SM, Lewis FA, Dixon MF, Taylor GR, Quirke P. Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology. Br J Cancer 1993;67:1262-7.
154. Cawkwell L, Lewis FA, Quirke P. Frequency of allele loss of DCC, p53, RBI, WT1, NF1, NM23 and APC/MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction. Br J Cancer 1994;70:813-8.
155. Carpenter KM, Durrant LG, Morgan K, Bennett D, Hardcastle JD, Kalsheker NA. Greater frequency of K-ras Val-12 mutation in colorectal cancer as detected with sensitive methods. Clin Chem 1996;42:904-9.
156. Carrithers SL, Barber MT, Biswas S, Parkinson SI, Park PK, Goldstein SD, et al. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci U S A 1996;93:14827-32.
157. Fujita S, Sugano K, Fukayama N, Moriya Y, Sugihara K, Akasu T. Detection of K-ras point mutations in mesenteric venous blood from colorectal cancer patients by enriched polymerase chain reaction and single-strand conformation polymorphism analysis. Jpn J Clin Oncol 1996;26:417-21.
158. Gotley DC, Fawcett J, Walsh MD, Reeder JA, Simmons DL, Antalis TM. Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer. Br J Cancer 1996;74:342-51.
159. Yoshida K, Sugino T, Bolodeoku J, Warren BF, Goodison S, Woodman A, et al. Detection of exfoliated carcinoma cells in colonic luminal washings by identification of deranged patterns of expression of the CD44 gene. J Clin Pathol 1996;49:300-5.
160. Gunn J, McCall JL, Yun K, Wright PA. Detection of micrometastases in colorectal cancer patients by K19 and K20 reverse-transcription polymerase chain reaction. Lab Invest 1996;75:611-6.
161. Juhl H, Roder C, Kruger U, Kremer B, Kalthoff H. The detection of disseminated tumor cells in bone marrow from colorectal cancer patients by a cytokeratin 20 specific nested reverse transcriptase-polymerase chain reaction is related to the stage of disease. Int J Cancer 1996;69:278-82.
162. Soeth E, Roder C, Juhl H, Kruger U, Kremer B, Kalthoff H. The detection of disseminated tumor cells in bone marrow from colorectal cancer patients by a cytokeratin 20 specific nested reverse transcriptase-polymerase chain reaction is related to the stage of disease. Int J Cancer 1996;69:278-82.
163. Funaki NO, Tanaka J, Itami A, Kasamatu T, Oshio G, Onodera H, et al. Detection of colorectal carcinoma cells in circulating peripheral blood by reverse transcription-polymerase chain reaction targeting cytokeratin-20 mRNA. Life Sci 1997;60:643-52.
164. Crabtree JE, Wyatt JI, Trejdosiewicz LK, Piechl P, Nichols PH, Ramsay N, et al. Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa. J Clin Pathol 1994;47:61-6.
165. Karttunen TJ, Genta RM, Yoffe B, Hachem CY, Graham DY, el-Zaatari FA. Detection of Helicobacter pylori in paraffin-embedded gastric biopsy specimens by in situ hybridization. Am J Clin Pathol 1996;106:305-11.
166. Nakamura S, Ueki T, Yao T, Ueyama T, Tsuneyoshi M. Epstein-Barr virus in gastric carcinoma with lymphoid stroma. Special reference to its detection by
167. Yokozaki H, Ito R, Nakayama H, Kuniyasu H, Taniyama K, Tahara E. Expression of CD44 abnormal transcripts in human gastric carcinomas. Cancer Lett 1994;83:229-34.
168. Fidalgo PO, Cravo ML, Chaves PP, Leitao CN, Mira FC. High prevalence of human papillomavirus in squamous cell carcinoma and matched normal esophageal mucosa: assessment by polymerase chain reaction. Cancer 1995;76:1522-8.
169. Noguchi S, Hiratsuka M, Furukawa H, Aihara T, Kasugai T, Tamura S, et al. Detection of gastric cancer micrometastases in lymph nodes by amplification of keratin 19 mRNA with reverse transcriptase-polymerase chain reaction. Jpn J Cancer Res 1996;87:650-4.
170. Morisaki T, Katano M, Ikubo A, Arian K, Nakamura M, Nakamura K, et al. Immunosuppressive cytokines (IL-10, IGF-beta) genes expression in human gastric carcinoma tissues. J Surg Oncol 1996;63:234-9.
171. Funaki NO, Tanaka J, Kasamatsu T, Oshio G, Hosotani R, Okino T, et al. Identification of carcinoembryonic antigen mRNA in circulating peripheral blood of pancreatic carcinoma and gastric carcinoma patients. Life Sci 1996;59:2187-99.
172. Komeda T, Fukuda Y, Sando T, Kita R, Furukawa M, Nishida N, et al. Sensitive detection of circulating hepatocellular carcinoma cells in peripheral venous blood. Cancer 1995; 75:2214-9.
173. Matsumura M, Niwa Y, Hikiba Y, Imamura M, Kato N, Shiina S, et al. Sensitive assay for detection of hepatocellular carcinoma associated gene transcription (alpha-fetoprotein mRNA) in blood. Biochem Biophys Res Commun 1995; 207:813-8.
174. Funaki NO, Tanaka J, Seto SI, Kasamatsu T, Kaido T, Imamura M. Hematogenous spreading of hepatocellular carcinoma cells: possible participation in recurrence in the liver. Hepatology 1997;25:564-8.
175. Niwa Y, Matsumura M, Shiratori Y, Inamura M, Kato N, Shinma P, et al. Quantitation of alpha-fetoprotein and albumin messenger RNA in human hepatocellular carcinoma. Hepatology 1996;23:1384-92.
176. Kar S, Carr BI. Detection of liver cells in peripheral blood of patients with advanced-stage hepatocellular carcinoma. Hepatology 1995;21:403-7.
177. Almoguera C, Shibata D, Forrester K, Martin I, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53:549-54.
178. Ajiki T, Onoyama H, Yamamoto M, Fujimori T, Maeda S, Saitoh Y. Detection of point mutations in K-ras gene at codon 12 in bile from percutaneous transhepatic choledochal drainage tubes for diagnosis of biliary strictures. Int J Pancreatol 1995;18:215-20.
179. Apple SK, Hecht JR, Novak JM, Nieberg RK, Rosenthal DL, Grody WW. Polymerase chain reaction-based K-ras mutation detection of pancreatic adenocarcinoma in routine cytology smears. Am J Clin Pathol 1996;105:321-6.
180. Motojima K, Tsunoda T, Kanematsu T, Nagata Y, Urano T, Shiku H. Distinguishing pancreatic carcinoma from other periampullary carcinomas by analysis of mutations in the Kirsten-ras oncogene. Ann Surg 1991;214:657-62.
181. Motojima K, Urano T, Nagata Y, Shiku H, Tsurifune T, Kanematsu T. Detection of point mutations in the Kirstenras oncogene provides evidence for the multicentricity of pancreatic carcinoma. Ann Surg 1993;217:138-43.
182. Rall CJ, Yan YX, Graeme-Cook F, Beauchamp R, Yandall DW, Povoski SP, et al. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma. Pancreas 1996;12:10-7.
183. Watanabe H, Sawabu N, Songur Y, Yamaguchi Y, Yamakawa D, Satomura Y, et al. Detection of K-ras point mutations at codon 12 in pure pancreatic juice for the diagnosis of pancreatic cancer by PCR-RFLP analysis. Pancreas 1996;12:18-24.
184. Nollau P, Moser C, Wagener C. Isolation of DNA from stool and bodily fluids for PCR amplification. Biotechniques 1996;20:784-8.
185. Kan M, Furukawa A, Aki M, Kanayama H, Kagawa S. Expression of CD44 splice variants in bladder cancer. Int J Urol 1995;2:295-301.
186. Yoshida K, Sugino T, Tahara H, Woodman A, Bolodeoku I, Nargund V, et al. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 1997;79:362-9.
187. Miyamoto H, Kubota Y, Shuin T, Toirgoe S, Hosaka M, Iwasaki Y, et al. Analyses of p53 gene mutations in primary human bladder cancer. Oncol Res 1993;5:245-9.
188. Kim KH, Kim YS. Analysis of p53 tumor suppressor gene mutations and human papillomavirus infection in human bladder cancers. Yonsei Med J 1995;36:322-31.
189. Kuczyk MA, Serth J, Hervatin C, Arnd T, Derendorf L, Thon WF, et al. Detection of p53 tumor-suppressor-gene protein in bladder tumors and prostate cancer: possible clinical implications. World J Urol 1994;12:345-51.
190. Vet JA, Bringuier PP, Poddighe PJ, Karthaus HF, Debruyne FM, Schalken JA, et al. p53 mutations have no additional prognostic value over stage in bladder cancer. Br J Cancer 1994;70:496-500.
191. Miyamoto H, Shuin T, Torigoe S, Iwasaki Y, Kubota Y. Retinoblastoma gene mutations in primary human bladder cancer. Br J Cancer 1995;71:831-5.
192. Burchill SA, Bradbury MF, Pittman K, Southgate J, Smith B, Selby P. Detection of epithelial cancer cells in peripheral blood by reverse transcriptase-polymerase chain reaction. Br J Cancer 1995;71:278-81.
193. Lonn U, Lonn S, Nylen U, Friberg S, Stenkvist B. Gene amplification detected in carcinoma cells from human urinary bladder washings by the polymerase chain reaction method. Cancer 1993;71:3605-10.
194. Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F, Sidransky D. Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci U S A 1994; 91:9871-5.
195. Kan M, Aki M, Akiyama K, Naruo S, Kanayama H, Kagawa S. High-level expression of the CD44 variant sharing exon v10 in renal cancer. Jpn J Cancer Res 1995;86:847-53.
196. Sarantou T, Chi DD, Garrison DA, Conrad AJ, Schmid P, Morton DL, et al. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 1997;57:1371-6.
197. Proebstle TM, Huber R, Sterry W. Detection of early micrometastases in subcutaneous fat of primary malignant melanoma patients by identification of tyrosinase-mRNA. Eur J Cancer B Oral Oncol 1996;32A:1664-7.
198. Pittman K, Burchill S, Smith B, Southgate J, Joffe J, Gore M, et al. Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann Oncol 1996;7:297-301.
199. Mellado B, Colomer D, Castel T, Munoz M, Carballo E, Galan M, et al. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol 1996;14:2091-7.
200. Reinhold U, Ludtke-Handjery HC, Schnautz S, Kreysel HW, Abken H. The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol 1997;108:166-9.
201. Schwurzer-Voit M, Proebstle TM, Sterry W. Identification of lymph node metastases by use of polymerase chain reaction (PCR) in melanoma patients. Eur J Cancer B Oral Oncol 1996;32A:264-8.
202. Gann PH, Hennekens CH, Stampher MJ. A prospective evaluation of plasma prostate specific antigen for detection of prostate cancer. JAMA 1995;273:289-94.
203. Stamey TA, Yang N, Hay AR, McNeal JE, Freina FS, Redwine E. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl J Med 1987;317:9911-6.
204. Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, con Eschenbach AC, et al. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 1995;45:470-5.
205. Crabbe DC, Peters J, Seeger RC. Rapid detection of MYCN gene amplification in neuroblastomas using the polymerase chain reaction. Diagn Mol Pathol 1992;1:229-34.
206. Ellis WJ, Vesella RL, Corey E. Use of a reverse transcriptase polymerase chain reaction (RT-PCR) to detect prostate cancer cells in the blood. J Urol 1996;155:378A.
207. Ignatoff JM, Oelfelein MG, Herz B, Watkin B, Kaul KL. Prostate specific antigen (PSA) reverse polymerase chain reaction (RT-PCR) assay in preoperative staging of prostate cancer. J Urol 1996;155:417A.
208. Dumas F, Eschwege P, Blanchet P. Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma using prostate specific membrane antigen (PSM) based nested reverse transcriptase polymerase chain reaction assay. J Urol 1996;155:506A.
209. Heston WD. Detection of hematogenous dissemination of prostatic cancer by RT-PCR with primers specific for prostate-specific membrane antigen [editorial]. Clin Chem 1995;41:1687-8.
210. Lintula S, Leioninen J, Stenman U. Expression of prostate specific membrane antigen mRNA peripheral blood of prostate cancer patients and healthy donors. J Urol 1996; 155:693A.
211. Amoils KD, Seymour L, Bezwoda WR. Comparison between immunocytochemical and polymerase chain reaction techniques for detection of oestrogen receptor and transforming growth factor beta in breast cancer. Br J Cancer 1996; 73:1255-9.
212. Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS. Sensitive detection of occult breast cancer by the reverse transcriptase polymerase chain reaction. J Clin Oncol 1994;12:475-82.
213. Iida N, Bourguignon LY. New CD44 splice variants associated with human breast cancers. J Cell Physiol 1995;162:127-33.
214. Maas RA, Bruning PF, Breedijk AJ, Top B, Peterse HL. Immunomagnetic purification of human breast carcinoma cells allows tumor-specific detection of multidrug resistance gene 1-mRNA by reverse transcriptase polymerase chain reaction in fine-needle aspirates. Lab Invest 1995;72:760-4.
215. Smith MR, Biggar S, Hussain M. Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases. Cancer Res 1995;55:2640-4.
216. Beckmann MW, Picard F, An HX, van Roeyen CR, Dominik SI, Mosny DS, et al. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Br J Cancer 1996;73:1220-6.
217. Ishioka C, Suzuki T, FitzGerald M, Krainer M, Shimodaira H, Shimada A, et al. Detection of heterozygous truncating mutations in the BRCA1 and APC genes by using a rapid screening assay in yeast. Proc Natl Acad Sci U S A 1997;94:2449-53.
218. Rohlfs EM, Learning WG, Friedman KJ, Couch FJ, Weber BL, Silverman LM, et al. Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clin Chem 1997;43:24-9.
219. Li BD, Harlow SP, Budnick RM, Sheedy DL, Stewart CC. Detection of HER-2/neu oncogene amplification in flow cytometry-sorted breast ductal cells by competitive polymerase chain reaction. Cancer 1994;73:2771-8.
220. Matsumura Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992;340:1053-8.
221. Dall P, Heider KH, Sinn HP, Skroch-Angel P, Adolf G, Kaufmann M, et al. Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer 1995;60:471-7.
222. Schoenfeld A, Luqmani Y, Smith D, O'Reilly S, Shousha S, Sinnet HD, et al. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res 1994;54:2986-90.
223. Kruger WH, Stockschlader M, Hennings S, Aschenbrenner M, Gruber M, Gutensohn K, et al. Detection of cancer cells in peripheral blood stem cells of women with breast cancer by RT-PCR and cell culture. Bone Marrow Transplant 1996;18(Suppl 1):S18-20.
224. Kruger W, Krzizanowski C, Holweg M, Kruger WH, Stockschlader M, Jung R, et al. Reverse transcriptase/polymerase chain reaction detection of cytokeratin-19 mRNA in bone marrow and blood of breast cancer patients. J Cancer Res Clin Oncol 1996;122:679-86.
225. Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994;12:475-82.
226. Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction: comparison between MUC1 mRNA and keratin 19 mRNA amplification. Am J Pathol 1996;148:649-56.
227. Moscinski LC, Trudeau WL, Fields KK, Elfenbein GJ. High-sensitivity detection of minimal residual breast carcinoma using the polymerase chain reaction and primers for cytokeratin 19. Diagn Mol Pathol 1996;5:173-80.
228. Traweek ST, Liu J, Battifora H. Keratin gene expression in non-epithelial tissues. Detection with polymerase chain reaction. Am J Pathol 1993;142:1111-8.
229. Luppi M, Morselli M, Bandieri E, Federico M, Marasca R, Barozzi P, et al. Sensitive detection of circulating breast cancer cells by reverse-transcriptase polymerase chain reaction of maspin gene. Ann Oncol 1996;7:619-24.
230. Chen CM, Shyu MP, Au LC, Chu HW, Cheng WT, Choo KB. Analysis of deletion of the integrated human papillomavirus 16 sequence in cervical cancer: a rapid multiplex polymerase chain reaction approach. J Med Virol 1994;44:206-11.
231. de Roda Husman AM, Snijders PJ, Stel HV, van den Brule AJ, Meijer CJ, Walboomers JM. Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction. Br J Cancer 1995;72:412-7.
232. de Roda Husman AM, Walboomers JM, Meijer CJ, Risse EK, Schipper ME, Helmerhorst TM, et al. Analysis of cytomorphologically abnormal cervical scrapes for the presence of 27 mucosotropic human papillomavirus genotypes, using polymerase chain reaction. Int J Cancer 1994;56:802-6.
233. De Sanjose S, Santamaria M, Alonso de Ruiz P, Aristizabal N, Guerrero E, Castellsagne X, et al. HPV types in women with normal cervical cytology. IARC Sci Publ 1992;119:75-84.
234. Franco E, Bergeron J, Villa L, Arella M, Richardson L, Arseneau J, et al. Human papillomavirus DNA in invasive cervical carcinomas and its association with patient survival: a nested case-control study. Cancer Epidemiol Biomarkers Prev 1996;5:271-5.
235. Melchers WJ, Claas HC, Quint WG. Use of the polymerase chain reaction to study the relationship between human papillomavirus infections and cervical cancer [review, 89 references]. Eur J Clin Microbiol Infect Dis 1991;10:714-27.
236. Pekonen F, Nyman T, Ammala M, Rutanen EM. Decreased expression of messenger RNAs encoding endothelin receptors and neutral endopeptidase 24.11 in endometrial cancer. Br J Cancer 1995;71:59-63.
237. Pekonen F, Nyman T, Rutanen EM. Differential expression of mRNAs for endothelin-related proteins in human endometrium, myometrium and leiomyoma. Mol Cell Endocrinol 1994;103:165-70.
238. Rencic A, Gordon J, Otte J, Curtis M, Kovatich A, Zoltick P, et al. Detection of JC virus DNA sequence and expression of the viral oncoprotein, tumor antigen, in brain of immunocompetent patient with oligoastrocytoma. Proc Natl Acad Sci U S A 1996;93:7352-7.
239. Frank S, Rihs HP, Stocker W, Muller J, Dumont B, Baur X, et al. Combined detection of CD44 isoforms by exon-specific RT-PCR and immunohistochemistry in primary human brain tumors and brain metastases. Biochem Biophys Res Commun 1996;222:794-801.
240. Li H, Liu J, Hofmann M, Hamou MF, de Tribolet N. Differential CD44 expression patterns in primary brain tumours and brain metastases. Br J Cancer 1995;72:160-3.
241. Brodeur GM. Clinical significance of genetic rearrangements in human neuroblastomas. Clin Chem 1989;35:B38-42.
242. Christiansen H, Delattre O, Fuchs S, Theobald M, Christiansen NM, Berthold F, et al. Loss of the putative tumor suppressor-gene locus 1p36 as investigated by a PCR-assay and N-myc amplification in 48 neuroblastomas: results of the German Neuroblastoma Study Group. Prog Clin Biol Res 1994;385:19-25.
243. Kuroda T, Saeki M, Nakano M, Mizutani S. Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction. J Pediatr Surg 1997;32:69-72.
244. Miyajima Y, Horibe K, Fukuda M, Matsumoto K, Numata S, Mori H, et al. Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer 1996;77:1214-9.
245. Miyajima Y, Kato K, Numata S, Kudo K, Horibe K. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer 1995;75:2757-61.
246. Mattano LA Jr., Moss TJ, Emerson SG. Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction. Cancer Res 1992; 52:4701-5.
247. Bouras M, Parvaz P, Berger N, Paulin C, Revol A. Ha-ras oncogene (codon 12) mutation in thyroid carcinogenesis: analysis of 60 benign and malignant thyroid tumors. Ann Biol Clin (Paris) 1995;53:549-55.
248. Ditkoff BA, Marvin MR, Yemul S, Shi YJ, Chabot J, Feind C, et al. Detection of circulating thyroid cells in peripheral blood. Surgery 1996;120:959-64 (discussion, 964-5).
249. Weiss M, Baruch A, Keydar I, Wreschner DH. Preoperative diagnosis of thyroid papillary carcinoma by reverse transcriptase polymerase chain reaction of the MUC1 gene. Int J Cancer 1996;66:55-9.
250. Corradini P, Voena C, Omede P, Astolfi M, Boccadoro M, Dalla-Favera R. et al. Detection of circulating tumor cells in multiple myeloma by a PCR-based method. Leukemia 1993;7:1879-82.
251. van Dongen GA, Brakenhoff RM, ten Brink CT, van Gog FB, de Bree R, Quak JJ, et al. Squamous cell carcinoma-associated antigens used in novel strategies for the detection and treatment of minimal residual head and neck cancer [review, 41 references]. Anticancer Res 1996;16:2409-13.
252. Califano J, Ahrendt SA, Meininger G, Westra WH, Koch WM, Sidransky D. Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. Cancer Res 1996;56:5720-2.
253. Slawin K, O'Hara M, Song W. Comparison of results obtained using different RT-PCR PSA assay methods on a single set of clinical specimens. J Urol 1996;155:417A.
254. Diamandis EP, Yu H. Prostate specific antigen immunoreactiviry in the milk of lactating women. Clin Chem 1994; 410:204-10.
255. Fadlon EJ, Rees RC, McIntyre C, Sharrard RM, Lawry J, Hamdy FC. Detection of circulating prostate-specific antigen-positive cells in patients with prostate cancer by flow cytometry and reverse transcription polymerase chain reaction. Br J Cancer 1996;74:400-5.
256. Hamdy FC, Lawry J, Anderson JB, Parsons MA, Rees RC, Williams JL. Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer. Br J Urol 1992;69:392-6.
257. Gomella LG, Raj GV, Moreno JG. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J Urol 1997;158:326-7.